Each day in Australia, three children enter the world carrying a genetic condition that will quietly build toward a heart attack before midlife — yet most will never receive a diagnosis in time to prevent it. Familial hypercholesterolaemia, a disorder of cholesterol processing present from birth, affects roughly one in 250 Australians, and the country's health system is failing to catch it during the years when intervention matters most. A new registry report has traced the precise contours of this failure, finding that diagnosis comes too late, genetic tools go underused, and the family-wide
Australian children with preventable heart disease missed through care gaps
Approximately 20,000 Australian children with familial hypercholesterolaemia remain undiagnosed and at risk of premature heart attacks and cardiovascular disease in adulthood.
Diagnosis in childhood can completely prevent premature heart disease
Mark
So this is a genetic condition that runs in families. How many Australian children are we actually talking about?
Mimi
About 20,000 children have familial hypercholesterolaemia right now. Three more are born with it every single day.
Luke
And how confident are we in those numbers? Are those diagnosed cases, or estimates of how many have it whether they know or not?
Mimi
The 20,000 is an estimate of total prevalence—one in 250 Australians. The registry report is specifically about children who have been identified and are in the system.
Mark
Which brings us to the core problem. They're not being caught early enough.
Mimi
Right. The ideal window for starting treatment is between six and ten years old. But the registry found children aren't being diagnosed until around age twelve on average.
Luke
What does "on average" hide? Are some being caught at six and others at sixteen, or is the whole cohort clustered around twelve?
Mimi
The report doesn't break that down in detail. But the point is clear—we're missing the optimal intervention window for most children.
Mark
And if you miss that window, what actually happens?
Mimi
Without treatment, people with FH have a twenty-fold increased risk of premature cardiovascular disease. Half of affected men will have a heart attack by fifty.
Luke
That's a stark number. Is that from long-term follow-up studies, or is it a calculated risk based on cholesterol levels?
Mimi
It's documented clinical outcome data. These aren't theoretical risks.
Mark
So the condition is treatable. What does treatment look like?
Mimi
Medication to lower cholesterol, ideally started in childhood. Early treatment can almost completely prevent the premature heart disease.
Mark
Then why aren't we screening for it?
Mimi
That's what the researchers are asking. The report found genetic testing has only been done on about half the children in the registry. And cascade testing—screening family members—is happening in fewer than half of cases.
Luke
Wait. If a child is diagnosed, wouldn't you automatically test their parents and siblings?
Mimi
You would think so. But the report shows it's not happening consistently across Australia.
Mark
So what's the fix?
Mimi
The researchers are calling for a national universal screening program in childhood, plus state-based cascade testing hubs.
Luke
Has any state actually implemented that yet?
Mimi
Western Australia is leading the way with the service at Perth Children's Hospital. But there's no national policy framework yet.
Mark
Which means the gaps will keep happening.
Mimi
Exactly. Without a coordinated national response, most Australian children with FH will remain undiagnosed.
El Pulso
- Three Australian children are born every day with a genetic disorder that carries a twentyfold risk of premature heart disease — and most will reach adulthood without ever knowing.
- A national registry report has exposed the fault lines: children are not diagnosed until nearly age twelve, well past the optimal treatment window of six to ten years old.
- Fewer than half of children already in care are hitting the cholesterol reduction targets that would protect their arteries, and genetic testing remains underused even among those already identified.
- Cascade testing — screening the relatives of diagnosed patients, the most efficient way to find new cases — is happening in fewer than half of instances, leaving entire family networks unexamined.
- Researchers are now pressing for a universal childhood screening program and state-based cascade testing hubs, with Western Australia already moving toward this model while the rest of the country waits for national policy to follow.
Each day in Australia, three children enter the world carrying a genetic condition that will quietly build toward a heart attack before midlife — yet most will never receive a diagnosis in time to prevent it. Familial hypercholesterolaemia, a disorder of cholesterol processing present from birth, affects roughly one in 250 Australians, and the country's health system is failing to catch it during the years when intervention matters most. A new registry report has traced the precise contours of this failure, finding that diagnosis comes too late, genetic tools go underused, and the family-wide screening that could multiply every detection remains rare. The tragedy is not that the condition is mysterious — it is that it is both well understood and eminently treatable, making the silence around it a choice the system has not yet chosen to undo.
Three children are born in Australia every day with a genetic disorder that will likely send them to hospital with a heart attack before they turn fifty. Most will never know they have it.
Familial hypercholesterolaemia, or FH, disrupts how the body processes cholesterol from birth. It affects roughly one in 250 Australians — around 100,000 adults and 20,000 children. The condition is both preventable and treatable, yet Australia is systematically failing to catch it in time. Left undetected, FH multiplies the risk of premature cardiovascular disease twentyfold. Half of affected men will suffer a heart attack by age fifty; a quarter of affected women by sixty. The window for intervention opens between ages six and ten and closes gradually as children grow older.
A new report from the Australian National FH Registry, published in the BMJ's Archives of Disease in Childhood, has mapped where the system is breaking down. Drawing on data from children's hospitals across Perth, Sydney, Queensland, Adelaide and beyond, it found that children with FH are not being identified until just before their twelfth birthday — well past the optimal treatment window. Fewer than half of those already in care are reaching recommended cholesterol reduction targets. Genetic testing has been used in only about half of registered children, and cascade testing of family members remains rare.
Associate Professor Andrew Martin, who leads the FH service at Perth Children's Hospital and directed the research, was direct: early diagnosis and management can completely prevent premature cardiovascular disease, but the system is missing critical opportunities to intervene. His team is calling for a universal childhood screening program, state-based cascade testing hubs, and rigorous national guidelines. Western Australia is already moving in this direction, but without a national policy framework, children will continue to grow into adulthood unaware of a risk that a simple test and early treatment could have erased.
Three children are born in Australia every day with a genetic disorder that, left untreated, will likely send them to hospital with a heart attack before they turn fifty. Most of them will never know they have it.
Familial hypercholesterolaemia, or FH, is a condition that disrupts how the body processes cholesterol from birth. It affects roughly one in every 250 Australians—about 100,000 adults and 20,000 children. The numbers alone suggest a public health problem of considerable scale. But the real problem is not the prevalence; it is that the condition is both preventable and treatable, and Australia is systematically failing to catch it in time.
When FH goes undetected and untreated, the risk of premature cardiovascular disease multiplies twentyfold. Half of affected men will suffer a heart attack by age fifty. A quarter of affected women will experience one by sixty. These are not speculative outcomes. They are documented consequences of a genetic accident that, with early intervention, can be almost entirely prevented. The window for that intervention opens early—ideally between ages six and ten—and closes gradually as children move into adolescence and adulthood.
A new report from the Australian National FH Registry, published in the British Medical Journal's Archives of Disease in Childhood, has mapped exactly where the system is breaking down. The registry, established in 2015 and based at the University of Western Australia, draws data from children's hospitals across the country: Perth, Westmead in Sydney, Queensland, Adelaide, and others. What it found should alarm anyone responsible for child health policy.
Children with FH are being diagnosed far too late. On average, they are not identified until just before their twelfth birthday—well past the optimal window for starting treatment. Fewer than half of the children already in treatment are reaching the recommended reduction in LDL cholesterol, the dangerous form that accumulates in arteries. Genetic testing, the most direct way to identify the condition, has been used in only about half of the children on the registry. And cascade testing—the practice of screening family members of diagnosed patients—remains rare, with fewer than half of the children identified through this method.
Associate Professor Andrew Martin, who leads the FH service at Perth Children's Hospital and directed the research, is direct about what these gaps mean. "Diagnosis and management from childhood can completely prevent premature cardiovascular disease," he said. "But our research shows we are missing important opportunities to intervene early." Without intervention, he added, the majority of Australian children with FH will remain undiagnosed and untreated—a missed opportunity that will likely cost lives.
The solution, according to Martin and his collaborators, requires a coordinated national response. They are calling for a universal screening program for FH in childhood, coupled with state-based cascade testing hubs and rigorous implementation of evidence-based guidelines. Western Australia, where much of this research is happening, is already moving in this direction. But without a national policy framework, the gaps will persist. Children will continue to be born with a preventable condition, grow into adolescence unaware of their risk, and enter adulthood on a collision course with heart disease that could have been averted with a simple test and early treatment.
Citas Notables
Diagnosis and management from childhood can completely prevent premature cardiovascular disease, but our research shows we are missing important opportunities to intervene early.— Associate Professor Andrew Martin, University of Western Australia and Perth Children's Hospital
Without a national universal screening program, the majority of Australian children with FH will remain undiagnosed and untreated—a missed opportunity to prevent future cardiovascular disease.— Associate Professor Andrew Martin
Quieres la nota completa?
Lee el original en nationaltribune.com.au ↗